We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Afriag | LSE:AFRI | London | Ordinary Share | IM00B3VVCM89 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.085 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
AfriAg Global PLC
(To be renamed Apollon Formularies PLC)
(“Company”)
12 April 2021
RESULT OF GENERAL MEETING
AND
AQUIS REGULATORY APPROVAL TO ACQUIRE APOLLON
The Company is pleased to announce that at the General Meeting of the Company held today, all resolutions were duly passed. The Company is also pleased to announce that AQSE Regulatory approval to be admitted to the AQSE Growth Market has now been received to acquire the entire issued share capital of Apollon Formularies Limited, and it is expected that admission to trading will commence tomorrow, 13 April 2021 at 8 a.m. The Enlarged Share Capital of 748,376,677 Ordinary Shares will be admitted to trading, comprising 31,710,011 Existing Ordinary Shares, 666,666,666 Consideration Shares and 50,000,000 Placing Shares and Subscription Shares.
The Directors of the Company accept responsibility for the contents of this announcement.
- Ends -
For additional information please contact:
AfriAg Global PLC
Stene Jacobs stene@apollon.org.uk
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller gm@peterhousecapital.com
Blytheweigh (Financial PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe tim.blythe@blytheweigh.com
Megan Ray megan.ray@blytheweigh.com
Copyright l 12 PR Newswire
1 Year Afriag Chart |
1 Month Afriag Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions